JP2024522092A5 - - Google Patents
Info
- Publication number
- JP2024522092A5 JP2024522092A5 JP2023572758A JP2023572758A JP2024522092A5 JP 2024522092 A5 JP2024522092 A5 JP 2024522092A5 JP 2023572758 A JP2023572758 A JP 2023572758A JP 2023572758 A JP2023572758 A JP 2023572758A JP 2024522092 A5 JP2024522092 A5 JP 2024522092A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- polypeptide
- effector
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193665P | 2021-05-27 | 2021-05-27 | |
| US63/193,665 | 2021-05-27 | ||
| EP21315127.7 | 2021-07-15 | ||
| EP21315127 | 2021-07-15 | ||
| PCT/IB2022/055019 WO2022249146A1 (en) | 2021-05-27 | 2022-05-27 | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522092A JP2024522092A (ja) | 2024-06-11 |
| JP2024522092A5 true JP2024522092A5 (enExample) | 2025-06-03 |
Family
ID=82358573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572758A Pending JP2024522092A (ja) | 2021-05-27 | 2022-05-27 | Ｆｃ受容体に対する親和性の増強および熱安定性の改善を伴うＦｃバリアント |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12297273B2 (enExample) |
| EP (1) | EP4347640A1 (enExample) |
| JP (1) | JP2024522092A (enExample) |
| KR (1) | KR20240015093A (enExample) |
| AU (1) | AU2022282666A1 (enExample) |
| BR (1) | BR112023022584A2 (enExample) |
| CA (1) | CA3216005A1 (enExample) |
| CO (1) | CO2023016432A2 (enExample) |
| IL (1) | IL308733A (enExample) |
| MX (1) | MX2023014100A (enExample) |
| TW (1) | TW202306584A (enExample) |
| WO (1) | WO2022249146A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR133427A1 (es) | 2023-07-31 | 2025-09-24 | Sanofi Sa | Anticuerpos anti-gprc5d y composiciones |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7312181B2 (en) | 2005-04-08 | 2007-12-25 | Cropsolution, Inc. | Acylated thiosemicarbazides as herbicides |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| MX2012004029A (es) * | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2013138643A1 (en) * | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| AR103488A1 (es) | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| AR107582A1 (es) * | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| AR108963A1 (es) | 2016-04-13 | 2018-10-17 | Merial Inc | Dispositivo de inyección con mecanismo de accionamiento para administrar múltiples formulaciones líquidas, tales como vacunas |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| CN108218998A (zh) * | 2017-12-31 | 2018-06-29 | 武汉班科生物技术股份有限公司 | 一种突变型人源IgG的Fc片段及其制备方法与应用 |
| BR112020015006A2 (pt) | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| JP7792330B2 (ja) * | 2019-09-03 | 2025-12-25 | アムジエン・インコーポレーテツド | Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法 |
-
2022
- 2022-05-27 TW TW111119900A patent/TW202306584A/zh unknown
- 2022-05-27 EP EP22726534.5A patent/EP4347640A1/en active Pending
- 2022-05-27 AU AU2022282666A patent/AU2022282666A1/en active Pending
- 2022-05-27 IL IL308733A patent/IL308733A/en unknown
- 2022-05-27 KR KR1020237044602A patent/KR20240015093A/ko active Pending
- 2022-05-27 US US17/826,295 patent/US12297273B2/en active Active
- 2022-05-27 MX MX2023014100A patent/MX2023014100A/es unknown
- 2022-05-27 WO PCT/IB2022/055019 patent/WO2022249146A1/en not_active Ceased
- 2022-05-27 JP JP2023572758A patent/JP2024522092A/ja active Pending
- 2022-05-27 CA CA3216005A patent/CA3216005A1/en active Pending
- 2022-05-27 BR BR112023022584A patent/BR112023022584A2/pt unknown
-
2023
- 2023-11-29 CO CONC2023/0016432A patent/CO2023016432A2/es unknown
-
2025
- 2025-03-26 US US19/091,594 patent/US20250376526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022218544B2 (en) | Hetero-dimeric multi-specific antibody format | |
| JP2024026255A5 (enExample) | ||
| JP7301540B2 (ja) | 抗体の混合物 | |
| IL276286B1 (en) | FC variants with improved binding to FCRN and extended half-life | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JP2021511830A5 (enExample) | ||
| AU2006251307B2 (en) | Method for the purification of antibodies | |
| JP7264381B2 (ja) | 血中半減期の向上のための抗体Ｆｃ変異体 | |
| JP2023534636A5 (enExample) | ||
| KR20210094610A (ko) | c-Kit에 대한 인간화 항체 | |
| JP2020506898A5 (enExample) | ||
| JP2012515556A5 (enExample) | ||
| JP2023103368A (ja) | アルブミン融合タンパク質を精製する方法 | |
| RS62151B1 (sr) | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu | |
| CA2502904A1 (en) | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis | |
| WO2005040217B1 (en) | Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions | |
| WO2021047559A1 (zh) | 一种断裂型内含肽、使用其的重组多肽的制备方法 | |
| JP2019506140A5 (enExample) | ||
| KR20230141817A (ko) | 이중특이 항체 | |
| JP2023508366A (ja) | 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法 | |
| JP2024507693A5 (enExample) | ||
| JP2022534433A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| CN117120478A (zh) | 一种抗原结合分子 | |
| JP2024531346A5 (enExample) | ||
| JP2024542235A5 (enExample) |